GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (STU:NKB2) » Definitions » Institutional Ownership

TG Therapeutics (STU:NKB2) Institutional Ownership : 33.69% (As of May. 28, 2024)


View and export this data going back to 2015. Start your Free Trial

What is TG Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, TG Therapeutics's institutional ownership is 33.69%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, TG Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, TG Therapeutics's Float Percentage Of Total Shares Outstanding is 90.45%.


TG Therapeutics Institutional Ownership Historical Data

The historical data trend for TG Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics Institutional Ownership Chart

TG Therapeutics Historical Data

The historical data trend for TG Therapeutics can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 36.02 33.74 35.00 32.60 33.94 34.83 34.76 34.37 34.44 33.69

TG Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


TG Therapeutics (STU:NKB2) Business Description

Traded in Other Exchanges
Address
3020 Carrington Mill boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

TG Therapeutics (STU:NKB2) Headlines

No Headlines